Supplemental material

Published: 26 February 2024| Version 1 | DOI: 10.17632/w6p652wrb9.1
Contributor:
Mette Gyldenløve

Description

Supplementary tables and figures from 'Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis – results from a randomized controlled trial (PSORRO)'

Files

Categories

Dermatology, Body Weight, Psoriasis, Medication

Licence